What is PlaqueTec?
PlaqueTec operates at the intersection of biotechnology and cardiology, specializing in the development of biomarker-based strategies for the management of Coronary Artery Disease (CAD). The company's core innovation, a sophisticated Liquid Biopsy System, enables the precise profiling of CAD biology, facilitating the identification of novel drug targets. By moving beyond traditional diagnostic methods, PlaqueTec is pioneering a new era of precision medicine aimed at addressing the leading cause of global mortality.
The company's market position is defined by its ability to build disease-specific cohorts, which provides invaluable data for pharmaceutical development and clinical decision-making. Through its rigorous research methodology, PlaqueTec is effectively reshaping the standard of care for cardiovascular health, offering a data-driven approach to prevention and treatment that promises to improve patient outcomes on a global scale.
How much funding has PlaqueTec raised?
PlaqueTec has raised a total of $13M across 2 funding rounds:
Other Financing Round
$8M
Other Financing Round
$5M
Other Financing Round (2024): $8M with participation from Future Fund
Other Financing Round (2026): $5M, investors not publicly disclosed
Key Investors in PlaqueTec
Future Fund
Future Fund is an Australian sovereign wealth fund established to invest for the benefit of future generations, focusing on long-term capital growth and financial stability.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PlaqueTec?
With the recent influx of capital, PlaqueTec is poised to advance its strategic roadmap, focusing on the commercialization of its diagnostic platform and the expansion of its clinical trial pipeline. The company is expected to prioritize the validation of its biomarker signatures, ensuring that its precision medicine tools meet the stringent requirements of global regulatory bodies.
Looking ahead, the firm will likely focus on strategic partnerships with pharmaceutical entities to integrate its liquid biopsy insights into drug discovery workflows. By maintaining a focus on high-impact research and scalable diagnostic solutions, PlaqueTec is set to remain a key player in the cardiovascular health sector, driving innovation that addresses the complex biological underpinnings of heart disease.
